Neuroendocrine prostate cancer (NEPC) encompasses various clinical contexts, ranging
from the de novo presentation of small cell prostatic carcinoma to a treatment-emergent …

Oligometastatic disease represents a clinical and anatomical manifestation between
localised and polymetastatic disease. In prostate cancer, as with other cancers, recognition …

Purpose Conventional radiotherapy (C-RT) treatment schedules for patients with prostate
cancer typically require 40 to 45 treatments that take place from> 8 to 9 weeks. Preclinical …

Purpose The aim of our study was to compare the diagnostic performance of 68 Ga-PSMA
PET and 99m Tc bone scintigraphy (BS) for the detection of bone metastases in prostate …

Background Early risk-stratified chemotherapy is a standard treatment for breast, colorectal,
and lung cancers, but not for high-risk localised prostate cancer. Combined docetaxel and …

Background: Impact of contemporary treatment of pre-invasive breast cancer (ductal
carcinoma in situ [DCIS]) on long-term outcomes remains poorly defined. We aimed to …

Background Active surveillance (AS) has become a well-accepted and widely used
treatment strategy. Objective To assess the long-term safety of AS for men with screen …

Purpose To evaluate the reproducibility of the combination of hybrid PET/MRI and the 68 Ga-
PSMA-11 tracer in depicting lymph node (LN) and bone metastases of prostate cancer (PC) …

The phosphatidylinositol 3-kinase (PI3K)/serine-threonine kinase (Akt)/mammalian target of
the rapamycin (mTOR)-signaling pathway has been suggested to have connections with the …

Methods After primary treatment, biochemical relapse (BCR) occurs in a substantial number
of patients with prostate cancer (PCa). PET/CT imaging with prostate-specific membrane …